ArticleResearch and practice in thrombosis and haemostasis2026
Association between coffee consumption and risk of recurrent venous thromboembolism - Results from the Trøndelag Health Study and Tromsø Study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiological studies have shown that coffee consumption is associated with a lowered risk of incident venous thromboembolism (VTE). No previous study has explored whether coffee consumption influences the risk of VTE recurrence. Objectives: This study aimed to investigate whether the amount of coffee consumption (cups/d) is associated with the risk of VTE recurrence in a population-based cohort of incident VTEs. Methods: The cohort consisted of 2071 patients with incident VTE recruited from 4 surveys of the Tromsø Study (enrolment, 1994-2008) and the third survey of the Trøndelag Health Study (enrolment, 2006-2008), followed from the date of the index VTE until 2020. Information on coffee consumption (cups/d) and potential confounders was extracted. Cox regression models were used to estimate hazard ratios (HRs) with 95% CIs for VTE recurrence. Results: During a median follow-up of 2.8 years, 310 recurrent VTEs occurred. There was no linear relationship between increasing coffee intake and VTE recurrence. The HR for recurrence was 0.49 (95% CI, 0.30-0.81) for those consuming 1 to 2 cups of coffee per day and 0.71 (95% CI, 0.44-1.12) for those consuming >6 cups compared with noncoffee consumers. The association between coffee consumption (yes/no) and lowered recurrence risk was more pronounced for provoked index VTE event (HR, 0.50; 95% CI, 0.30-0.82) than for unprovoked index VTE (HR, 1.01; 95% CI, 0.53-1.94). Conclusion: Coffee consumption was associated with a nonlinear, lowered risk of VTE recurrence, particularly after provoked VTE. Our findings suggest that coffee can be safely consumed after VTE, potentially with a beneficial effect on recurrence risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.